may have an additive effect on potassium retention, resulting in hyperkalemia.
Those with heart failure who were taking potassium-sparing diuretics
had significantly lower rates of hospitalization and death from worsening heart failure, as well as lower cardiac event rates, than those who were taking non-potassium-sparing diuretics
POTASSIUM-SPARING DIURETICS All potassium-sparing diuretics
have a weak antihypertensive effect when used by themselves.
Antihypertensive agents in general reduced the risk for Alzheimer's disease (AD), but the potassium-sparing diuretics
were particularly beneficial, said Dr.
b) The beneficial effect on urinary excretion may be similar to action of potassium-sparing diuretics
due to unchanged potassium levels in the Se-SM group
Patients with moderate renal impairment who are taking medications that interfere with potassium excretion, such as potassium-sparing diuretics
, or medications that interfere with the renin-angiotensin-aldosterone system are more likely to develop hyperkalemia.
Caution should be exercised when using these therapies in patients with severe CKD concomitantly using one or a combination of the following medications: ARBs, non-steroidal anti-inflammatory agents (NSAIDs), potassium supplements, and potassium-sparing diuretics
When broken down further by subtypes of antihypertensive agents, the potassium-sparing diuretics
had the most significant protective effect, with a 73% reduction in risk for Alzheimer's disease.
Also contraindicated in people on potassium supplements, potassium-sparing diuretics
(amiloride, spironolactone, or triamterene), and drugs that are strong inhibitors of CYP450 3A4, such as ketoconazole or itraconazole.
Spironolactone HCl is a synthetic 17-lactone drug that is a renal competitive aldosterone antagonist in the class of pharmaceuticals known as potassium-sparing diuretics
Decrease potassium replacement if serum potassium is raised or decrease/stop potassium-sparing diuretics
Fifty-four subjects (mean age, 74 years) had physician-diagnosed hypertension for which they took beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, potassium-sparing diuretics
, alpha-blockers, or a combination of these drugs.
Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics
, potassium supplements, and/or potassium-containing salt substitutes.
, potassium supplements, or potassiumCaecontaining salt substitutes may lead to significant increases in serum potassium.